Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.11.2022 | Case report

Paclitaxel

Grade 3 arthralgia: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Li J-J, et al. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology 148: 1159-1169, No. 5, May 2022. Available from: URL: http://doi.org/10.1007/s00432-021-03700-9 Li J-J, et al. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology 148: 1159-1169, No. 5, May 2022. Available from: URL: http://​doi.​org/​10.​1007/​s00432-021-03700-9
Metadaten
Titel
Paclitaxel
Grade 3 arthralgia: case report
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-28738-7

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Dexamethasone

Case report

Pembrolizumab

Case report

Dobutamine

Case report

Valproic acid